75 results on '"Lazzarin, A."'
Search Results
2. SAT-220-Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation
3. SAT-220-Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation
4. SAT-404-Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients
5. Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects
6. SAT-404-Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients
7. Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals
8. Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients
9. Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects
10. Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study
11. Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients
12. Real-Life Experience of Daa-Based Regimens Plus Ribavirin in Cirrhotic Patients Coinfected with HCV and HIV-1
13. Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study
14. Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study
15. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
16. P0909 : Analysis of natural resistance profile to NS5A replication complex inhibitors in different Hepatitis C genotypes
17. P0588 : Immune response to hepatitis B vaccination in HIV infected individuals with isolated antibodies to HBV core antigen
18. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
19. P224 DIFFERENT PROFILE OF NATURAL RESISTANCE TO NS3 PROTEASE INHIBITORS IN HEPATITIS C SUBTYPES 1A AND 1C
20. P0588 : Immune response to hepatitis B vaccination in HIV infected individuals with isolated antibodies to HBV core antigen
21. P0909 : Analysis of natural resistance profile to NS5A replication complex inhibitors in different Hepatitis C genotypes
22. P224 DIFFERENT PROFILE OF NATURAL RESISTANCE TO NS3 PROTEASE INHIBITORS IN HEPATITIS C SUBTYPES 1A AND 1C
23. P1240 CHARACTERIZATION OF HCV-1 SUBTYPES AND NATURAL RESISTANCE TO PROTEASE INHIBITORS IN LIVER AND PLASMA COMPARTMENTS OF HIV/HCV COINFECTED INDIVIDUALS
24. SAT-205 - Real-Life Experience of Daa-Based Regimens Plus Ribavirin in Cirrhotic Patients Coinfected with HCV and HIV-1
25. SAT-162 - Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study
26. SAT-147 - Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
27. FRI-180 - Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study
28. 1211 AMINO ACID CHANGE IN THE POSITIONS ASSOCIATED WITH PROTEASE INHIBITORS RESISTANCE IS LESS FREQUENT IN GENOTYPE 3 THAN IN GENOTYPE 1 HCV NATURAL STRAIN
29. 1211 AMINO ACID CHANGE IN THE POSITIONS ASSOCIATED WITH PROTEASE INHIBITORS RESISTANCE IS LESS FREQUENT IN GENOTYPE 3 THAN IN GENOTYPE 1 HCV NATURAL STRAIN
30. Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment
31. 1195 TEMPORAL DYNAMIC OF MUTATIONS ASSOCIATED WITH HCV PROTEASE INHIBITORS RESISTANCE IN NATURAL STRAINS OF HIV/HCV COINFECTED INDIVIDUALS
32. The NS3 protease gene of HCV is highly conserved within the putative catalytic site region
33. 1195 TEMPORAL DYNAMIC OF MUTATIONS ASSOCIATED WITH HCV PROTEASE INHIBITORS RESISTANCE IN NATURAL STRAINS OF HIV/HCV COINFECTED INDIVIDUALS
34. [570] MUTATIONS IN THE NATURAL STRAINS OF NS3 PROTEASE DOMAIN THAT CONFER RESISTANCE TO ANTI-HCV PROTEASE INHIBITORS IN HIV/HCV COINFECTED PATIENTS
35. [570] MUTATIONS IN THE NATURAL STRAINS OF NS3 PROTEASE DOMAIN THAT CONFER RESISTANCE TO ANTI-HCV PROTEASE INHIBITORS IN HIV/HCV COINFECTED PATIENTS
36. 92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN)
37. 389 Comparison of hepatitis C virus population in plasma, peripheral blood mononuclear cells (PBMC) and cerebrospinal fluid (CSF) of HIV/HCV coinfected patients
38. 556 Mutations in the NS3 protease domain of HCV in HIV/HCV coinfected patients under antiretroviral therapy (ART)
39. The NS3 protease gene of HCV is highly conserved within the putative catalytic site region
40. Hepatitis C virus infection in HIV-infected long term non progressors (LTNPS)
41. Prevalence of a 660 amino acid substitution in the PePHD region of HCV-E2 protein in hepatocellular carcinoma
42. Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment
43. 92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN)
44. 389 Comparison of hepatitis C virus population in plasma, peripheral blood mononuclear cells (PBMC) and cerebrospinal fluid (CSF) of HIV/HCV coinfected patients
45. Hepatitis C virus infection in HIV-infected long term non progressors (LTNPS)
46. Evolution of the E2 region of hepatitis C virus in an infant infectedby mother-to-infant transmission
47. Prevalence of a 660 amino acid substitution in the PePHD region of HCV-E2 protein in hepatocellular carcinoma
48. Evolution of the E2 region of hepatitis C virus in an infant infectedby mother-to-infant transmission
49. Mother to child transmission of hepatitis C virus detected by nested polymerase chain reaction
50. Mother to child transmission of hepatitis C virus detected by nested polymerase chain reaction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.